GLP-1 RAs Hold Promising Potential for Reduction of Cardiometabolic Risk Factors additional benefits : Brain: Appetite suppression, nerve protection, and decreased neuroinflammation Heart: Decreased blood pressure (systolic and diastolic), reduced total cholesterol levels, lowered endothelial dysfunction, and increased heart rate Liver: Decreased glucose production Pancreas: Increased insulin secretion, decreased glucagon secretion, B islet cell proliferation GI Tract: Decreased gastric emptying Because these drugs cause weight loss, it is not clear whether the GLP-1 RAs or the weight loss reduces cardiometabolic risks
Clinical evidence from the STEP trials demonstrated that higher doses produce greater weight loss, with the 2.4 mg dose resulting in approximately 15% body weight reduction over 68 weeks compared to placebo
By the end of the day, I just dragged myself home and went to bed. Ozempic, Wegovy, and other semaglutides are part of a drug class called glucagon-like peptide 1 (GLP-1) agonists, which mimic the action of a specific peptide and stimulate the production of more insulinlowering blood sugar as a result
So whisper-soft signals, such as a 5% incidence of nausea that persists beyond three weeks in your treated population, could go unnoticed until much, much later, he explained